LEXINGTON, Mass.--(BUSINESS WIRE)--CoNCERT Pharmaceuticals Inc., the first company dedicated to creating safer, more effective medicines using precision deuterium chemistry, announced today the addition of two new members to its Product Advisory Board (PAB). The PAB, now comprising seven members, was established at CoNCERT’s inception as a source of deep industry expertise to help evaluate and contribute to development and commercialization strategies for the Company’s product pipeline. The two most recent additions strengthen the PAB in the areas of marketing and commercial operations: W. James O’Shea, former President and Chief Operating Officer, and most recently Vice Chairman of Sepracor Inc. (NASDAQ: SEPR); and Daniel Grau, M.Phil., Chief Operating Officer of CombinatoRx, Incorporated (NASDAQ: CRXX).
